From hiking to office productivity to smart home control, download these 10 apps and take better control of your life with ...

Friday, January 24, 2025 – Morgan Wallen unveiled the title of his fourth studio album, "I'm The Problem ... If I Know Me "Like a lot of people my age, I didn't necessarily grow up listening to ...

Below is the full interview with Micone with the full transcript. Nevada Sagebrush: Michael, why did you initially choose the ...

DexCom , Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems for diabetes management with a market capitalization of $34.8 billion, finds itself at a critical juncture as it ...

Its non-GAAP profit of $0.45 per share was 9.9% below analysts’ consensus estimates. Is now the time to buy DexCom ... companies face challenges from high R&D costs and reliance on regulatory ...

Dexcom stock tumbled late Thursday after the diabetes devices maker missed Wall Street's fourth-quarter profit expectations.

“And if it’s the whiskey/then why you keep on pullin’ it off the shelf?/You hate that when you look at me, you halfway see yourself/and it got me thinkin’/if I’m the problem ...

In addition, you can check the fund’s top 5 holdings to determine its best picks for 2024. Aristotle Atlantic Focus Growth Strategy highlighted stocks like DexCom, Inc. (NASDAQ:DXCM), in the ...

But just when you think that he's starting to believe the accusations himself, he turns the argument on its head. "If I'm the problem, well, you might be the reason," he sings at the end of the ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Hold rating on Dexcom (DXCM – Research Report), with a price target of $82.00. The company’s shares closed yesterday ...

Barclays analyst Matt Miksic maintained a Hold rating on Dexcom (DXCM – Research Report) today and set a price target of $90.00. The company’s shares closed yesterday at $84.09. Leverage the ...